Glaucoma News and Research

Latest Glaucoma News and Research

Optometrists and dietitians are important part of health care team

For people with diabetes, proper nutrition can have a far-reaching effect on their health and wellness. They also have a higher risk of developing vision problems. March is National Nutrition Month and Save Your Vision Month, and the American Dietetic Association (ADA) and American Optometric Association (AOA) would like to remind people that optometrists and registered dietitians are an important part of the health care team.

31 Mar 2010

Vision CRC scientists discover new technology to control myopia

Scientists from the Vision Cooperative Research Centre in Australia today announced that myopia, or short-sightedness, can be controlled with new technology. This ground breaking discovery was based on research conducted by Vision CRC partners - the University of Houston College of Optometry and the Brien Holden Vision Institute, located at the University of New South Wales.

31 Mar 2010

Alcon acquires right to market DUREZOL ophthalmic corticosteroid in U.S.

Alcon, the world's leader in eye care, announced today that it received regulatory approval and finalized the acquisition of the rights in the United States for DUREZOL™ emulsion and the global rights, excluding Latin America, for ZYCLORIN™ from Sirion Therapeutics, Inc.

30 Mar 2010

SENSIMED Triggerfish developed to diagnose and treat patients with glaucoma

STMicroelectronics, the world's leading supplier of MEMS (Micro-Electro-Mechanical Systems) devices for consumer and portable applications, has announced that it will develop and supply a wireless MEMS sensor that acts as a transducer, antenna and mechanical support for additional read-out electronics in a breakthrough platform developed by Swiss company Sensimed AG.

26 Mar 2010

New topical drug may help treat diabetic eye disease

Early-stage human clinical trials showed that a new topical drug was safe and had biological effects in a type of diabetic eye disease, and may offer researchers a new approach to prevent and treat diabetic macular edema.

26 Mar 2010

EMA accepts MAA filing of ViroPharma's Cinryze for HAE

ViroPharma Incorporated today announced that the European Medicines Agency (EMA) has accepted the filing of its Marketing Authorization Application for Cinryze for acute treatment and prophylaxis against hereditary angioedema, which was submitted through the centralized procedure in March 2010. ViroPharma is seeking European approval for both prevention and treatment of acute attacks of hereditary angioedema.

25 Mar 2010

American Association of Poison Control Centers: K2 herbal marijuana substitute spurred poison calls

K2, an herbal marijuana substitute also known as "spice," is a blend of herbs sprayed with a synthetic marijuana-like drug, and has spurred at least 112 calls to U.S. poison centers since 2009, including 59 calls since March 1, 2010.

25 Mar 2010

Special medicated contact lenses can help treat common eye disorders

The popular dietary supplement vitamin E, loaded into special medicated contact lenses, can keep glaucoma medicine near the eye - where it can treat that common disease- almost 100 times longer than possible with current commercial lenses, scientists reported here today.

25 Mar 2010

FDA approves Custom Spine's anterior cervical interbody device

Custom Spine announced today that it has received FDA clearance to market PATHWAY ACIF, an anterior cervical interbody spacer. This cervical interbody device compliments the company's low-profile anterior cervical plate system, Regent ACP, which was released this past November.

25 Mar 2010

High-density genotyping array launched to study complexity of mouse genetics

Affymetrix, Inc. and The Jackson Laboratory today announced the full commercial launch of the Affymetrix® Mouse Diversity Genotyping Array. This is the first high-density genotyping array that enables researchers to study the complexity of the mouse genome and the diversity among mouse strains.

24 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

FDA approves Somaxon Pharmaceuticals' Silenor for treatment of insomnia

Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.

19 Mar 2010

StockPreacher.com: ACAD reports net loss of $8.7M for fourth-quarter of 2009

StockPreacher.com announces an investment report featuring ACADIA Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

17 Mar 2010

OVD issue highlights prevalence of eye problems in general population

In the latest issue of Optometry & Vision Development (OVD), Dr. Dominick Maino, editor of OVD, notes that: "In 2010 there are 9 million people with lazy eye and 18 million individuals with eye-turns

17 Mar 2010

Promedior raises $12M in Series C financing

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.

16 Mar 2010

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate).

12 Mar 2010

New MMMCC center improves patients’ access to medical marijuana

Marijuana is not just for brownies anymore. It has touched the lives of thousands of Michigan residents who are struggling with chronic pain, severe nausea, seizures, spasms or wasting syndrome.

12 Mar 2010

QLT announces results from Phase II clinical trials and device study for PPDS

QLT Inc. today announced results from Phase II clinical trials and a device study for the punctal plug delivery system (PPDS). These studies are part of a development program that is being conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc. QLT also announced its plans to expand the program to evaluate a second drug for a new target indication.

11 Mar 2010

Lowering levels of Coonexin46 with use of siRNA will help prevent tumor formation

What began as research into how diabetics could possibly preserve their eyesight has led to findings that could prolong the vision of children afflicted with retinoblastoma.

10 Mar 2010

Aton Pharma introduces authorized generic version of Timoptic-XE

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has launched an authorized generic version of its Timoptic-XE® (timolol maleate ophthalmic gel forming solution). Timoptic-XE is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Aton also announced that it will continue to make available branded Timoptic-XE.

9 Mar 2010